Somnairsleep

Somnair operates at the intersection of medical devices, sleep health, neurotechnology, and digital health. Its proposed product is differentiated from conventional continuous positive airway pressure systems by using a custom-fitted oral appliance to deliver non-invasive neurostimulation, rather than relying on an external mask-based airflow system. It also differs from passive mandibular-advancement oral appliances because the core approach is active stimulation rather than mechanical repositioning alone. The company’s early positioning is nevertheless distinctive: it is pursuing a first-in-class device for obstructive sleep apnea while combining oral-device form factors with neurostimulation. Its inclusion in the 2025 Rosenman Innovators cohort and Pepperdine’s 2025 Most Fundable Companies list provides evidence of early ecosystem recognition, but not of market share or clinical adoption. With only one disclosed seed round and a reported employee range of one to ten, Somnair remains an early-stage product-development company rather than an established commercial competitor.

Somnair’s trajectory reflects a transition from founding and product development into early financing and external validation. The company was founded in 2024 and identifies Anders Sideris, Mitchell Turley, Phoebe Dijour, and Shri Prabha Shivram as founders. By Jun 24, 2025, Somnair had been selected as a UCSF Rosenman Innovator, signaling recognition of its non-invasive neurostimulation approach for sleep apnea. The company then recorded a $4,322,853 seed round on Jul 7, 2025, led by J2 Ventures. That financing represents the principal disclosed growth inflection point and is intended to support development of the custom-fitted oral appliance. Recognition on Pepperdine Graziadio’s 2025 Most Fundable Companies list followed on Nov 13, 2025. Growth remains difficult to quantify because no hiring expansion, product launch, regulatory milestone, revenue figure, or follow-on round is disclosed. The current employee signal indicates one to ten employees, while only one current position is specifically listed. Overall, Somnair shows early capital formation and institutional recognition, but its next trajectory will depend on clinical validation, regulatory progress, manufacturing readiness, and conversion of the prototype concept into an adopted treatment.